Literature DB >> 18753927

Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.

Kurt Van Baelen1, Veerle Van Eygen, Evelien Rondelez, Lieven J Stuyver.   

Abstract

The contribution of clade-specific polymorphisms in the HIV-1 integrase gene towards integrase inhibitor phenotypic susceptibility was tested on 137 clinical isolates, of which 60 were non-clade B strains. Control Q148R mutant virus showed fold change values of 17.85 +/- 2.77 and 88.94 +/- 9.02 for raltegravir and elvitegravir, respectively, whereas the average fold change for the clinical samples was 0.91 +/- 0.40, and 0.84 +/- 0.37. Phenotypic testing proved that clade-specific integrase polymorphisms do not contribute to reduced susceptibility towards integrase inhibitors.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18753927     DOI： 10.1097/QAD.0b013e32830f9703

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  12 in total

1.  Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.

Authors:  Daniele Armenia; Ina Vandenbroucke; Lavinia Fabeni; Herwig Van Marck; Valeria Cento; Roberta D'Arrigo; Liesbeth Van Wesenbeeck; Fernanda Scopelliti; Valeria Micheli; Bianca Bruzzone; Sergio Lo Caputo; Jeroen Aerssens; Giuliano Rizzardini; Valerio Tozzi; Pasquale Narciso; Andrea Antinori; Lieven Stuyver; Carlo Federico Perno; Francesca Ceccherini-Silberstein
Journal:  J Infect Dis       Date:  2012-01-11       Impact factor: 5.226

2.  Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.

Authors:  Francesca Ceccherini-Silberstein; Kurt Van Baelen; Daniele Armenia; Maria Trignetti; Evelien Rondelez; Lavinia Fabeni; Fernanda Scopelliti; Michela Pollicita; Liesbeth Van Wesenbeeck; Veerle Van Eygen; Luca Dori; Loredana Sarmati; Stefano Aquaro; Guido Palamara; Massimo Andreoni; Lieven J Stuyver; Carlo Federico Perno
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

3.  Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

Authors:  S P Korolev; Yu Yu Agapkina; M B Gottikh
Journal:  Acta Naturae       Date:  2011-07       Impact factor: 1.845

4.  The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes.

Authors:  Saleta Sierra; Nadine Lübke; Hauke Walter; Eugen Schülter; Stefan Reuter; Gerd Fätkenheuer; Markus Bickel; Hugo da Silva; Rolf Kaiser; Stefan Esser
Journal:  Med Microbiol Immunol       Date:  2011-04-08       Impact factor: 3.402

Review 5.  HIV-1 antiretroviral drug therapy.

Authors:  Eric J Arts; Daria J Hazuda
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 6.  HIV resistance to raltegravir.

Authors:  Francois Clavel
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175

7.  Raltegravir: The evidence of its therapeutic value in HIV-1 infection.

Authors:  Kavya Ramkumar; Nouri Neamati
Journal:  Core Evid       Date:  2010-06-15

8.  The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.

Authors:  Sandrine Reigadas; Guerric Anies; Bernard Masquelier; Christina Calmels; Lieven J Stuyver; Vincent Parissi; Herve Fleury; Marie-Line Andreola
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

Review 9.  Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.

Authors:  Jamie D Croxtall; Susan J Keam
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

10.  Raltegravir in the management of HIV-infected patients.

Authors:  Hans-Jürgen Stellbrink
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.